Deflazacort

Phase 3Terminated

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Limb-Girdle Muscular Dystrophy

Conditions

Limb-Girdle Muscular Dystrophy

Trial Timeline

Oct 31, 2019 → Jan 1, 2021

NCT ID

NCT03783923

About Deflazacort

Deflazacort is a phase 3 stage product being developed by PTC Therapeutics for Limb-Girdle Muscular Dystrophy. The current trial status is terminated. This product is registered under clinical trial identifier NCT03783923. Target conditions include Limb-Girdle Muscular Dystrophy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02592941	Pre-clinical	Completed	—	—	Duchenne Muscular Dystrophy
NCT03783923	Phase 3	Terminated	Oct 31, 2019	Jan 1, 2021	Limb-Girdle Muscular Dystrophy
NCT03642145	Phase 3	Withdrawn	Oct 31, 2018	Jul 31, 2021	Duchenne Muscular Dystrophy
NCT02485431	Phase 1	Completed	Jun 1, 2015	Aug 1, 2015	Healthy Volunteers
NCT02251600	Phase 1	Completed	Dec 1, 2014	Oct 1, 2015	Duchenne Muscular Dystrophy
NCT02295748	Phase 1	Completed	Dec 1, 2014	Aug 24, 2017	Duchenne Muscular Dystrophy
NCT02286609	Phase 1	Completed	Dec 1, 2014	Feb 1, 2015	Hepatic Impairment
NCT02286622	Phase 1	Completed	Dec 1, 2014	Feb 1, 2015	Renal Impairment

Competing Products

3 competing products in Limb-Girdle Muscular Dystrophy

See all competitors

Product	Company	Stage	Hype Score
SRP-9005 + Corticosteroid	Sarepta Therapeutics	Phase 3	72
SRP-9003 + Glucocorticoid	Sarepta Therapeutics	Phase 3	72
ATYR1940 + Placebo	aTyr Pharma	Phase 1/2	33

Other Products from PTC Therapeutics

Ataluren + PlaceboPhase 3

AtalurenPhase 3

Ataluren (PTC124®) + PlaceboPhase 3

Ataluren + PlaceboPhase 3

Ataluren + PLACEBOPhase 3